Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Aduro Biotech's Total Stockholders Equity for the quarter that ended in Jun. 2020 was $46.62 Mil. Aduro Biotech's Total Assets for the quarter that ended in Jun. 2020 was $265.38 Mil.
Therefore, Aduro Biotech's Equity to Asset Ratio for the quarter that ended in Jun. 2020 was 0.18.
The historical rank and industry rank for Aduro Biotech's Equity-to-Asset or its related term are showing as below:
ADRO's Equity-to-Asset is not ranked *
in the Biotechnology industry.
Industry Median: 0.66 * Ranked among companies with meaningful Equity-to-Asset only.
Aduro Biotech Equity-to-Asset Historical Data
The historical data trend for Aduro Biotech's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Aduro Biotech's Equity-to-Asset
For the Biotechnology subindustry, Aduro Biotech's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aduro Biotech's Equity-to-Asset Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Aduro Biotech's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Aduro Biotech's Equity-to-Asset falls into.
Aduro Biotech Equity-to-Asset Calculation
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Aduro Biotech's Equity to Asset Ratio for the fiscal year that ended in Dec. 2019 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Aduro Biotech Equity-to-Asset Related Terms
Thank you for viewing the detailed overview of Aduro Biotech's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.
Aduro Biotech (Aduro Biotech) Business Description
Aduro Biotech Inc is a immunotherapy company focused on the discovery, development and commercialization of therapies that are designed to harness the body's natural immune system for the treatment of patients with challenging diseases. Its primary technologies related are to the Stimulator of Interferon Genes (STING) and A Proliferation Inducing Ligand. The STING pathway activator technology is designed to activate the intracellular STING receptor. The APRIL is a soluble factor that binds to BCMA and TACI receptors thereby inducing signaling, and is implicated in IgA nephropathy.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ADRO has been successfully added to your 